百济神州 2022年度报告

*Included in connection with the registration of the American Depositary Shares with the Securities and ExchangeCommission. The ordinary shares are not listed for trading in the United States but are listed for trading on The StockExchange of Hong Kong Limited. As of November 1, 2023, 1,359,497,624 ordinary shares, par value $0.0001 per share, were outstanding, of which871,833,599 ordinary shares were held in the form of 67,064,123 American Depositary Shares, each representing 13ordinary shares, and 115,055,260 were RMB shares. Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant wasrequired to file such reports); and (2) has been subject to such filing requirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or forsuch shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”“accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Accelerated filer☐Non-accelerated filer☐Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of theExchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ Table of Contents BeiGene, Ltd.Quarterly Report on Form 10-QTABLE OF CONTENTS Page PART I.FINANCIAL INFORMATION3Item 1.Financial Statements3Item 2.Management’s Discussion and Analysis of Financial Condition and Resultsof Operations29Item 3.Quantitative and Qualitative Disclosures about Market Risk42Item 4.Controls and Procedures43PART II.OTHER INFORMATION44Item 1.Legal Proceedings44Item 1A.Risk Factors44Item 2.Unregistered Sales of Equity Securities, Use of Proceeds and IssuerPurchases of Equity Securities103Item 3.Defaults Upon Senior Securities103 PART I.FINANCIAL INFORMATION Item 1.Financial Statements BEIGENE, LTD.CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data) Table of Contents The accompanying notes are an integral part of these condensed consolidated financialstatements.5 Table of Contents BEIGENE, LTD.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Amounts in thousands of U.S. Dollars (“$”))(Unaudited) The accompanying notes are an integral part of these condensed consolidated financialstatements.6 Table of Contents The accompanying notes are an integral part of these condensed consolidated financial statements.7 Table of Contents BEIGENE, LTD. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Amounts in thousands of U.S. Dollar (“$”) and Renminbi (“RMB”), except for number of sharesand per share data) (Unaudited) 1. Description of Business, Basis of Presentation and Consolidation and Significant AccountingPolicies Description of business BeiGene, Ltd. (the “Company”, “BeiGene”, “it”, “its”) is a global biotechnology company that isdiscovering and developing innovative oncology treatments that are more accessible and affordable tocancer patients worldwide. The Company currently has three approved medicines that were internally discovered and developed,including BRUKINSA®, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment ofvarious blood cancers; TEVIMBRA®(tislelizumab), an anti-PD-1 antibody immunotherapy for thetreatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor ofPARP1 and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, thePeople's Republic of China (“China” or the “PRC”), the European Union, the United Kingdom, Canada,Australia and additional international markets; tislelizumab in the European Union and China; andpamiparib in China. By leveraging its strong commercial capabilities, the Company has in-licensed therights to distribute an additional 14 approved medicines for the China market. Supported by its globalclinical development and commercial capabilities, the Company has entered into collaborations with world-leading biopharmaceutical companies such as Amgen Inc. (“Amgen”) and Novartis Pharma AG(“Novartis”) to develop and commercialize innovative medicines. The Company is co